183 related articles for article (PubMed ID: 38638430)
1. An updated review of immunotherapy in esophageal cancer: PD-L1 footprint.
Yao J; Tan X; Sha Y; Chen Y; Chen R; Shi D
Cent Eur J Immunol; 2024; 49(1):77-90. PubMed ID: 38812606
[TBL] [Abstract][Full Text] [Related]
2. PTMs of PD-1/PD-L1 and PROTACs application for improving cancer immunotherapy.
Ren X; Wang L; Liu L; Liu J
Front Immunol; 2024; 15():1392546. PubMed ID: 38638430
[TBL] [Abstract][Full Text] [Related]
3. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
4. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
Feng C; Zhang L; Chang X; Qin D; Zhang T
Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
[TBL] [Abstract][Full Text] [Related]
5. PROTACs: Novel tools for improving immunotherapy in cancer.
Li S; Chen T; Liu J; Zhang H; Li J; Wang Z; Shang G
Cancer Lett; 2023 Apr; 560():216128. PubMed ID: 36933781
[TBL] [Abstract][Full Text] [Related]
6. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
[TBL] [Abstract][Full Text] [Related]
7. Dysregulation of PD-L1 by UFMylation imparts tumor immune evasion and identified as a potential therapeutic target.
Zhou J; Ma X; He X; Chen B; Yuan J; Jin Z; Li L; Wang Z; Xiao Q; Cai Y; Zou Y; Cong YS
Proc Natl Acad Sci U S A; 2023 Mar; 120(11):e2215732120. PubMed ID: 36893266
[TBL] [Abstract][Full Text] [Related]
8. The E3 ubiquitin ligases regulate inflammation in cardiovascular diseases.
Chen X; Ma J; Wang ZW; Wang Z
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):167-174. PubMed ID: 36872193
[TBL] [Abstract][Full Text] [Related]
9. The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy.
Hou B; Chen T; Zhang H; Li J; Wang P; Shang G
Front Immunol; 2023; 14():1123244. PubMed ID: 36733484
[TBL] [Abstract][Full Text] [Related]
10. Peptide-based PROTACs: Current Challenges and Future Perspectives.
Wang H; Chen M; Zhang X; Xie S; Qin J; Li J
Curr Med Chem; 2024; 31(2):208-222. PubMed ID: 36718000
[TBL] [Abstract][Full Text] [Related]
11. Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.
Su W; Tan M; Wang Z; Zhang J; Huang W; Song H; Wang X; Ran H; Gao Y; Nie G; Wang H
Angew Chem Int Ed Engl; 2023 Mar; 62(11):e202218128. PubMed ID: 36647763
[TBL] [Abstract][Full Text] [Related]
12. Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer.
Yang H; Zhang X; Lao M; Sun K; He L; Xu J; Duan Y; Chen Y; Ying H; Li M; Guo C; Lu Q; Wang S; Su W; Liang T; Bai X
Cell Death Differ; 2023 Feb; 30(2):560-575. PubMed ID: 36539510
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
